| __timestamp | Madrigal Pharmaceuticals, Inc. | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 15746000 | 13774000 |
| Thursday, January 1, 2015 | 13392000 | 22479000 |
| Friday, January 1, 2016 | 9290000 | 27388000 |
| Sunday, January 1, 2017 | 7672000 | 35610000 |
| Monday, January 1, 2018 | 15293000 | 49007000 |
| Tuesday, January 1, 2019 | 22648000 | 61139000 |
| Wednesday, January 1, 2020 | 21864000 | 68836000 |
| Friday, January 1, 2021 | 37318000 | 97592000 |
| Saturday, January 1, 2022 | 48130000 | 106903000 |
| Sunday, January 1, 2023 | 108146000 | 120998000 |
Unleashing the power of data
In the competitive world of biotechnology, managing costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Madrigal Pharmaceuticals, Inc. and Vericel Corporation from 2014 to 2023. Over this period, Vericel consistently outpaced Madrigal in SG&A spending, with a notable 88% increase from 2014 to 2023. Madrigal, on the other hand, saw a staggering 587% rise in the same timeframe, reflecting its aggressive expansion strategy.
By 2023, Vericel's SG&A expenses reached approximately $121 million, a 780% increase from 2014, while Madrigal's expenses soared to about $108 million. This trend highlights the differing strategic priorities of these companies, with Vericel focusing on steady growth and Madrigal on rapid expansion. Understanding these financial dynamics offers valuable insights into the operational strategies of leading biotech firms.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Vericel Corporation
Breaking Down SG&A Expenses: argenx SE vs Vericel Corporation
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Vericel Corporation
Selling, General, and Administrative Costs: BeiGene, Ltd. vs Madrigal Pharmaceuticals, Inc.
Bio-Techne Corporation or Madrigal Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Alpine Immune Sciences, Inc.
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or CymaBay Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Madrigal Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Madrigal Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Madrigal Pharmaceuticals, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation